Show simple item record

dc.contributor.authorDe Miguel Pérez, Diego
dc.contributor.authorSerrano Fernández, María José
dc.identifier.citationde Miguel-Perez, D... [et al.]. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res 41, 186 (2022). []es_ES
dc.description.abstractBackground: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs.es_ES
dc.description.sponsorshipCenter for Thoracic Oncology Icahn School of Medicine at Mount Sinaies_ES
dc.description.sponsorshipBorsa Dottorati FSE XXXII ciclo Unimees_ES
dc.description.sponsorshipUnited States Department of Health & Human Serviceses_ES
dc.description.sponsorshipNational Institutes of Health (NIH) - USAes_ES
dc.description.sponsorshipNIH National Cancer Institute (NCI) P30CA016672es_ES
dc.description.sponsorshipUniversity of Pittsburgh Hillman Cancer Centeres_ES
dc.description.sponsorshipHillman Cancer Center's NCI Cancer Center Support Grant (CCSG) P30CA047904es_ES
dc.description.sponsorshipA.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onluses_ES
dc.description.sponsorshipNational Cancer Institute-Cancer Center Support Grant (CCSG) P30CA134274es_ES
dc.description.sponsorshipMerck & Companyes_ES
dc.rightsAtribución 3.0 España*
dc.subjectExtracellular vesicleses_ES
dc.subjectImmunotherapy es_ES
dc.titleExtracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung canceres_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España